论文部分内容阅读
目的分析卡培他滨维持化疗治疗晚期和术后复发转移胃癌的效果及安全性。方法选择2008—2011年在上饶市上饶县人民医院经6个周期全身化疗后缓解的晚期及术后复发转移的胃癌患者80例,将患者按治疗方法不同分为观察组与对照组,各40例。两组患者经全身化疗后予以常规对症支持治疗,观察组在常规治疗基础上口服卡培他滨治疗。观察两组患者的生存情况及毒副作用情况。结果观察组患者生存时间长于对照组,差异有统计学意义(P<0.05);观察组患者1、2年生存率高于对照组(P<0.0);观察组患者毒副作用发生率为45.0%,对照组为40.0%,两组患者毒副作用发生率比较,差异无统计学意义(P>0.05)。结论卡培他滨维持化疗治疗晚期和术后复发转移胃癌的效果显著,可延长患者生存时间,改善其生活质量,且不增加毒副作用,安全性高。
Objective To analyze the effect and safety of capecitabine in the maintenance of chemotherapy for advanced and postoperative recurrence and metastasis of gastric cancer. Methods Eighty patients with advanced gastric cancer who relapsed after 6 cycles of systemic chemotherapy in Shangrao County People’s Hospital of Shangrao City from 2008 to 2011 were divided into observation group and control group according to the different treatment methods example. Patients in both groups were given conventional symptomatic and supportive treatment after systemic chemotherapy. The observation group was treated with capecitabine on the basis of routine treatment. Survival status and side effects of two groups were observed. Results The survival time of the observation group was longer than that of the control group (P <0.05). The 1-year and 2-year survival rates of the observation group were higher than those of the control group (P <0.0). The incidence of side effects in the observation group was 45.0% , And 40.0% in control group. There was no significant difference between the two groups in the incidence of side effects (P> 0.05). Conclusion The effect of capecitabine on chemotherapy of advanced and postoperative recurrence and metastasis of gastric cancer is significant, which can prolong the survival time of patients and improve their quality of life without increasing the side effects and high safety.